Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jan 11, 2022
Trial Information
Current as of August 11, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special treatment program delivered through phone or online can help patients with chronic liver disease who are also struggling with unhealthy alcohol use. Participants in the trial will be divided into two groups: one group will receive a stepped alcohol treatment that includes motivational support and a referral to addiction specialists if needed, while the other group will receive standard care. The study aims to see how effective this approach is over 6 and 12 months.
To be eligible for the trial, participants must be at least 18 years old, have chronic liver disease, and show unhealthy patterns of alcohol use, which means drinking more than moderate amounts in the past month. They should also be able to access a phone or a device like a computer or smartphone for the sessions. Participants will be monitored for their progress, and those who qualify will be informed about what to expect during the study. This research could provide valuable insights into improving care for people with liver disease and alcohol-related issues.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Men and women age ≥ 18 years.
- • 2. Diagnosis of chronic liver disease (CLD).
- • 3. Unhealthy alcohol use, defined as more than moderate amount of alcohol use within the prior 30 days by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria defined as on average more than 1 drink/day (7 drinks per week) for women and more than 2 drinks per day (14 drinks per week) for men, or on average at least one heavy drinking day (4+ drinks in a day for women and 5+ for men) per week in the prior 30 days. A standard drink is \~14 g of alcohol.
- • 4. Ability to access a telephone or a digital device (i.e., computer, tablet or smart phone).
- Exclusion criteria:
- • 1. Severe medical or psychiatric conditions or evidence of acute alcohol intoxication preventing participation in the study
- • 2. Are currently enrolled in formal treatment for unhealthy alcohol use, excluding self or mutual-help groups (e.g., Alcoholics Anonymous).
- • 3. Women who are pregnant or breastfeeding or unwilling to use birth control.
- • 4. Language preference other than English, Spanish or Chinese.
- • 5. Unwilling or unable to provide informed consent.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
San Francisco, California, United States
Patients applied
Trial Officials
Mandana Khalili, M.D.
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials